Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and preven...
Saved in:
Main Authors: | Ching-Chi Lee, Chih-Chia Hsieh, Wen-Chien Ko |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/74981b2833ae44b6bb4f9ec78331bb5d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Molnupiravir; an effective drug in treating COVID-19?
by: Alireza Pouramini, et al.
Published: (2022) -
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease
by: Maria L. Agostini, et al.
Published: (2018) -
Antiviral research
Published: (1981) -
A Novel Intronic Circular RNA Antagonizes Influenza Virus by Absorbing a microRNA That Degrades CREBBP and Accelerating IFN-β Production
by: Zhiyuan Qu, et al.
Published: (2021) -
Identification of the I38T PA Substitution as a Resistance Marker for Next-Generation Influenza Virus Endonuclease Inhibitors
by: Jeremy C. Jones, et al.
Published: (2018)